A randomized trial comparing alizapride alone or with dexamethasone vs a metoclopramide-dexamethasone combination for emesis induced by moderate-dose cisplatin

Camillo F. Pollera, Mario Nardi, Paolo Marolla, Paolo Carlini

Research output: Contribution to journalArticlepeer-review

Abstract

To evaluate the antiemetic effectiveness and toxicity of a novel congener of metoclopramide (MCP), alizapride (AZP), 29 patients receiving cisplatin (50 mg/m2) alone or with adriamycin (40 mg/m2) were entered into a randomized cross-over trial comparing moderate-dose AZP (2 mg/kg for 4 doses) administered alone or with dexamethasone (DXM) (8 mg for five doses) vs a standard combination of MCP (1 mg/kg for four doses) and DXM (as above). With the dosage and schedule used, AZP provided only limited antiemetic protection, with less than 10% of the patients free of emesis. The AZP-DXM combination was significantly more effective than AZP alone in reducing the intensity of the emesis (P

Original languageEnglish
Pages (from-to)335-338
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume19
Issue number4
DOIs
Publication statusPublished - Jul 1987

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A randomized trial comparing alizapride alone or with dexamethasone vs a metoclopramide-dexamethasone combination for emesis induced by moderate-dose cisplatin'. Together they form a unique fingerprint.

Cite this